Compare SSKN & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSKN | CYCN |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 7.6M |
| IPO Year | 2005 | N/A |
| Metric | SSKN | CYCN |
|---|---|---|
| Price | $1.44 | $1.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 83.8K | ★ 1.1M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,980,000.00 | $2,855,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1371.65 |
| 52 Week Low | $1.24 | $1.28 |
| 52 Week High | $3.86 | $6.25 |
| Indicator | SSKN | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 50.25 |
| Support Level | $1.24 | $1.48 |
| Resistance Level | $1.53 | $1.73 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 68.97 | 87.50 |
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.